Article Text

PDF
Lack of association between PADI4 and functional severity in Japanese rheumatoid arthritis patients
  1. K Nishimoto1,
  2. K Ikari2,
  3. T Mochizuki2,
  4. T Tomatsu2,
  5. Y Toyama1,
  6. M Hara2,
  7. H Yamanaka2,
  8. N Kamatani2,
  9. S Momohara2
  1. 1
    Department of Orthopedic Surgery, School of Medicine, Keio University, Tokyo, Japan
  2. 2
    Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
  1. K Ikari, Institute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawada, Shinjuku, Tokyo 162-0054, Japan; kikari{at}ior.twmu.ac.jp

Statistics from Altmetric.com

Clinical presentation of rheumatoid arthritis (RA) varies from mild deformity of small joints to mutilating severe arthritis causing remarkable functional disorder and restriction of daily life activities. Prediction of disease outcome may allow better targeting of aggressive treatment. Recently, anti-cyclic citrullinated peptide antibody (anti-CCP) has been reported to be associated with disease outcomes.15 Peptidylarginine deiminase type 4 (PADI4), encoding citrullinating enzyme, was identified as one of the RA susceptibility genes and was also reported to be associated with the level of anti-CCP in RA patients.6 These findings suggest the hypothesis that PADI4 determines disease severity of RA as well as its susceptibility. Our aim was to investigate the association between …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.